132 related articles for article (PubMed ID: 23593983)
1. Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs.
Nishimuta H; Nakagawa T; Nomura N; Yabuki M
Xenobiotica; 2013 Nov; 43(11):948-55. PubMed ID: 23593983
[TBL] [Abstract][Full Text] [Related]
2. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
[TBL] [Abstract][Full Text] [Related]
3. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
Nishimuta H; Houston JB; Galetin A
Drug Metab Dispos; 2014 Sep; 42(9):1522-31. PubMed ID: 24994071
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.
Prueksaritanont T; Gorham LM; Hochman JH; Tran LO; Vyas KP
Drug Metab Dispos; 1996 Jun; 24(6):634-42. PubMed ID: 8781778
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs.
van Beusekom CD; Schipper L; Fink-Gremmels J
J Vet Pharmacol Ther; 2010 Dec; 33(6):519-27. PubMed ID: 21062303
[TBL] [Abstract][Full Text] [Related]
6. Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.
Furukawa T; Naritomi Y; Tetsuka K; Nakamori F; Moriguchi H; Yamano K; Terashita S; Tabata K; Teramura T
Xenobiotica; 2014 Mar; 44(3):205-16. PubMed ID: 23962030
[TBL] [Abstract][Full Text] [Related]
7. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine.
Martignoni M; Groothuis G; de Kanter R
Drug Metab Dispos; 2006 Jun; 34(6):1047-54. PubMed ID: 16565172
[TBL] [Abstract][Full Text] [Related]
9. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes.
Nishimuta H; Watanabe T; Bando K
AAPS J; 2019 Jan; 21(2):20. PubMed ID: 30673906
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
[TBL] [Abstract][Full Text] [Related]
13. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.
Emoto C; Yoda N; Uno Y; Iwasaki K; Umehara K; Kashiyama E; Yamazaki H
Curr Drug Metab; 2013 Feb; 14(2):239-52. PubMed ID: 22963393
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
15. Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human.
Bueters T; Juric S; Sohlenius-Sternbeck AK; Hu Y; Bylund J
Xenobiotica; 2013 Jul; 43(7):607-16. PubMed ID: 23278250
[TBL] [Abstract][Full Text] [Related]
16. Presystemic metabolism of AZ'0908, a novel mPGES-1 inhibitor: an in vitro and in vivo cross-species comparison.
Bylund J; Bueters T
J Pharm Sci; 2013 Mar; 102(3):1106-15. PubMed ID: 23316000
[TBL] [Abstract][Full Text] [Related]
17. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.
Yoda N; Emoto C; Date S; Kondo S; Miyake M; Nakazato S; Umehara K; Kashiyama E
Xenobiotica; 2012 Aug; 42(8):719-30. PubMed ID: 22324396
[TBL] [Abstract][Full Text] [Related]
18. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.
Iwatsubo T; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):462-9. PubMed ID: 9353358
[TBL] [Abstract][Full Text] [Related]
19. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
